NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 12 May 2021

**Location:** Via Zoom

## **Committee members present**

1. Professor Gary McVeigh (Chair) Present for all items
2. Dr Lindsay Smith (Vice Chair) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Present for items 3 to 3.2.2
5. Professor Sofia Dias Present for items 1 to 2.2.2
6. Professor Rachel Elliott Present for all items
7. Professor Paula Ghaneh Present for all items
8. Rebecca Harmston Present for all items
9. Christopher Herring Present for all items
10. Dr Andrew Hitchings Present for all items
11. Dr Robert Hodgson Present for all items
12. Dr Bernard Khoo Present for all items
13. Dr Soo Fon Lim Present for all items
14. Dr Guy Makin Present for all items
15. Professor David Meads Present for all items
16. Giles Monnickendam Present for all items
17. Malcolm Oswald Present for all items
18. Dr Rebecca Payne Present for all items
19. Professor Chris Parker Present for all items
20. Baljit Singh Present for all items
21. Professor John Watkins Present for all items

## **NICE staff present:**

Linda Landells, Associate Director Present for all items

Kate Moore, Project Manager Present for all items

Victoria Kelly, Technical Adviser Present for items 1 to 2.2.2

Caron Jones, Technical Adviser Present for items 3 to 3.2.2

Anita Sanga, Technical Analyst Present for items 1 to 2.2.2

Amy Crossley, Technical Analyst Present for items 3 to 3.2.2

Sarah Wilkes, Technical Analyst Present for all items

Maroulla Whiteley, Business Analyst, RIA Present for all items

Helen Barnett, Senior Medical Editor Present for items 1 to 2.2.2

Ann Greenwood, Senior Medical Editor Present for items 3 to 3.2.2

Emily Eaton Turner, Commercial Risk Assessment Team Present for items 1 to 2.2.2

Claire Hawksworth, Commercial Risk Assessment Team Present for items 3 to 3.2.2

Mandy Tonkinson, Public Involvement Adviser Present for items 1 to 2.1.3

Catherine Pank, Assistant Project Manager, COT Present for items 3 to 3.2.2

Lucinda Evans, Coordinator, MIP Present for items 1 to 2.1.3 & 3 to 3.2.2

Gemma Smith, Coordinator, COT Present for all items

Sandra Robinson, Coordinator, MIP Present for items 1 to 2.1.3 & 3 to 3.2.2

Toni Shaw, Information Specialist Present for items 1 to 2.1.3

Celia Mayers, Administrator Present for all items

Daniel Greenwood, Assistant Administrator Present for items 3 to 3.2.2

Emma Kent, Data Collection Manager Present for items 1 to 2.2.2

## **External group representatives present:**

Nigel Armstrong, Kleijnen Systematic Reviews Present for items 1 to 2.1.3

Sabine Grimm, Kleijnen Systematic Reviews Present for items 1 to 2.1.3

Peter Murphy, Centre for Reviews and Dissemination and Centre for Health Economics – York, Present for items 3 to 3.1.3

Ruth Walker, Centre for Reviews and Dissemination and Centre for Health Economics – York, Present for items 3 to 3.1.3

## **Clinical & patient experts present:**

Professor Peter Clark, CDF Clinical Lead, NHS England, Present for items 3 to 3.2.2  
Professor Chris Edwards, Consultant Rheumatologist, clinical expert nominated by GSK Present for items 1 to 2.1.3

Dr Peter Lanyon, Consultant Rheumatologist, clinical expert nominated by NHS England Specialised Rheumatology Clinical Reference Group, Present for items 1 to 2.1.3

Kim Opszala, Patient expert nominated by LUPUS UK , Present for items 1 to 2.1.3

Jane Robinson, Patient expert nominated by NHS England Specialised Rheumatology Clinical Reference Group, Present for items1 to 2.1.3

Introduction to the meeting

* 1. The chair Professor Gary McVeigh welcomed members of the committee and other attendees present to the meeting.

Appraisal of belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus - Review of TA397 [ID1591]

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from GlaxoSmithKline.
     2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Chris Edwards declared financial and professional interest as he has received honoraria for attending advisory boards and speaking events from GSK & Roche. He is an author on publications related to the BILAG biologics registry in the UK and a member of the BILAG group.
* It was agreed that his declaration would not prevent Professor Edwards from providing expert advice to the committee.
* Dr Peter Lanyon declared professional interests as he Is the National Clinical Lead for Rheumatology, GIRFT Programme and NHS Improvement and co-chair of Autoimmune Rheumatic Disease Alliance (RAIRDA) – whose membership includes LUPUS UK.
* It was agreed that his declaration would not prevent Dr Lanyon from providing expert advice to the committee.
* Committee member Dr Matthew Bradley is an employee of the manufacturer of belimumab which as a direct conflict meant that Dr Bradley did not attend the meeting for this topic.
* No further conflicts of interest were declared for this item.
  + 1. The Chair introduced the lead team Professor Rachel Elliott, Rebecca Harmston and Professor John Watkins who gave presentations on the clinical effectiveness and cost effectiveness of belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus - review of TA397.
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.

Appraisal of nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

* 1. Part 1 – Open session
     1. The chair Professor Gary McVeigh welcomed the invited external group representatives, the CDF clinical lead from NHS England, members of the public and company representatives from Bristol-Myers Squibb.
     2. The chair asked all committee members, the CDF clinical lead from NHS England, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor David Meads declared an indirect financial interest as the University of Leeds has received funding from Celgene and Bristol-Myers Squibb for research in an unrelated area.
* It was agreed that his declaration would not prevent Professor Meads from providing expert advice to the committee.
* Committee member Professor Sofia Dias is also part of the York ERG team who carried out the assessment for this appraisal and therefore as a direct conflict Professor Dias did not attend the meeting for this topic.
* No further conflicts of interest were declared for this item.
  + 1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session [company representatives, external group representatives and members of the public were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.

1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee D) will be held on Thursday 17 June 2021 and will start promptly at 9.30am.